216 related articles for article (PubMed ID: 33529725)
1. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Ala M
Eur J Pharmacol; 2021 Apr; 896():173921. PubMed ID: 33529725
[TBL] [Abstract][Full Text] [Related]
2. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
3. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.
Chen JY; Li CF; Kuo CC; Tsai KK; Hou MF; Hung WC
Breast Cancer Res; 2014 Jul; 16(4):410. PubMed ID: 25060643
[TBL] [Abstract][Full Text] [Related]
4. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Johnson TS; Munn DH
Immunol Invest; 2012; 41(6-7):765-97. PubMed ID: 23017145
[TBL] [Abstract][Full Text] [Related]
5. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
6. IDO/kynurenine pathway in cancer: possible therapeutic approaches.
Abd El-Fattah EE
J Transl Med; 2022 Aug; 20(1):347. PubMed ID: 35918736
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
8. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Brochez L; Chevolet I; Kruse V
Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
10. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.
da Silva Dias IC; Carabelli B; Ishii DK; de Morais H; de Carvalho MC; Rizzo de Souza LE; Zanata SM; Brandão ML; Cunha TM; Ferraz AC; Cunha JM; Zanoveli JM
Mol Neurobiol; 2016 Dec; 53(10):6997-7009. PubMed ID: 26671617
[TBL] [Abstract][Full Text] [Related]
12. Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome.
Maria NI; van Helden-Meeuwsen CG; Brkic Z; Paulissen SM; Steenwijk EC; Dalm VA; van Daele PL; Martin van Hagen P; Kroese FG; van Roon JA; Harkin A; Dik WA; Drexhage HA; Lubberts E; Versnel MA
Arthritis Rheumatol; 2016 Jul; 68(7):1688-99. PubMed ID: 26866723
[TBL] [Abstract][Full Text] [Related]
13. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
Shibata Y; Hara T; Nagano J; Nakamura N; Ohno T; Ninomiya S; Ito H; Tanaka T; Saito K; Seishima M; Shimizu M; Moriwaki H; Tsurumi H
PLoS One; 2016; 11(1):e0146279. PubMed ID: 26727596
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment.
Azimnasab-Sorkhabi P; Soltani-Asl M; Yoshinaga TT; Zaidan Dagli ML; Massoco CO; Kfoury Junior JR
Mol Biol Rep; 2023 Jul; 50(7):6133-6145. PubMed ID: 37217614
[TBL] [Abstract][Full Text] [Related]
15. A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis.
Xiang Z; Li J; Song S; Wang J; Cai W; Hu W; Ji J; Zhu Z; Zang L; Yan R; Yu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):314. PubMed ID: 31315643
[TBL] [Abstract][Full Text] [Related]
16. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
17. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Triplett TA; Garrison KC; Marshall N; Donkor M; Blazeck J; Lamb C; Qerqez A; Dekker JD; Tanno Y; Lu WC; Karamitros CS; Ford K; Tan B; Zhang XM; McGovern K; Coma S; Kumada Y; Yamany MS; Sentandreu E; Fromm G; Tiziani S; Schreiber TH; Manfredi M; Ehrlich LIR; Stone E; Georgiou G
Nat Biotechnol; 2018 Sep; 36(8):758-764. PubMed ID: 30010674
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
19. IDO1: An important immunotherapy target in cancer treatment.
Li F; Zhang R; Li S; Liu J
Int Immunopharmacol; 2017 Jun; 47():70-77. PubMed ID: 28365507
[TBL] [Abstract][Full Text] [Related]
20. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
